SPECIAL FEATURE - Injection Devices: Advancements Converge to Expand Patient Possibilities
Cindy H. Dubin speaks with injection device developers about creating devices that are intelligent, intuitive, patient-centric systems that make advanced therapies easier, safer, and more accessible to use at home.
ARTIFICIAL INTELLIGENCE - AI/ML Supporting Biomarker & Target Discovery
William Whitford explains how Artificial Intelligence/Machine Learning provide new capabilities in analyzing the rapidly increasing type and amount of biological data employed in identifying potential biomarker and disease targets.
EXECUTIVE INTERVIEW - Portal Instruments: Beyond Springs – Portal Prime Nexus™ Autoinjector is a Versatile Solution for Biologics
As biologics become larger, more viscous, and more complex, software offers a fundamentally better way to control and optimize delivery.
PLATFORM TECHNOLOGY - How a Novel Immunotherapy Platform is Unlocking the Cancer-Fighting Potential of Unconventional T Cells
Michal Sheleg, PhD, shines a spotlight on the promise of MAIT cells to fight cancer by turning to an untapped source: human placentas.
FORMULATION FORUM - High Concentration Biologics for Injectable Drug Delivery
Shaukat Ali, PhD, and Jim Huang, PhD, discuss how the development of high- and ultra-high-concentration biologics aims to enable smaller-volume, patient-friendly subcutaneous injections.
BIOPHARMA MARKET LAUNCH - De-risking Global Market Entry Through Redundant Capacity & Flexible Manufacturing
John Ward and Paul Hamill stress that launch readiness matters as much as development progress. Thus global expansion is shifting to a near-term priority and CDMOs can reduce the risk of a global launch through agile downstream execution.
DELIVERY SYSTEM DEVELOPMENT - Supporting Earlier Delivery-System Decisions in Injectable Drug Development Through a USP <382>-Aligned System-Level Approach
Sarah Masucci and Crystal Salvans highlight a shift from evaluating individual syringe components independently toward system-level qualification of the complete PFS container-closure system, with the goal of simplifying development and supporting product quality and regulatory expectations.
LYOPHILIZATION - Great Expectations: Selecting & Managing CDMO Partnerships for Lyophilized Injectables from Development Through Commercialization
Carrie A. Schults outlines considerations of managing these partnerships with an emphasis on proactive risk management to control timelines and cost.
QUALITY MANAGEMENT SYSTEM - One QMS, Four Delivery Platforms: Can Your Quality System Manage Complexity at Scale?
Melanie Cerullo emphasizes that when quality systems manage rather than react to complexity, faster development and safer more effective medicines ensue.
REGULATORY COMPLIANCE - Navigating ISO 23908:2024 & EN ISO 23908:2025 Harmonization: What It Means for Your Combination Product Strategy
Murtaza Rana and Aurélie Rebuffet reflect on how a revised standard is an opportunity to reassess how sharps injury risks are addressed across product development, regulatory submissions, and lifecycle management
25 Years of Trust, Partnership & Progress
To Our Readers, Advertising Partners, and Industry Colleagues, When Drug Development & Delivery began in 2001, the pharmaceutical and life sciences landscape looked very different…
2026 Sustainable Drug Development & Delivery eBook: Pharma Needs A Risk-Based Strategy Toward Sustainability
As sustainability expectations continue to rise across the pharmaceutical industry, drug makers, CDMOs, and equipment suppliers are under increasing pressure to reduce waste, energy use, and environmental impact. Find out in this exclusive Drug Development & Delivery eBook how companies like Bespak have taken steps to support the scale of commercial-scale manufacturing of a low-carbon Pressurized Metered Dose Inhaler. Additionally, learn how Aptar Pharma Injectables division has undertaken an effort to identify the principal sources of emissions across its elastomeric closure solutions. Finally, a new sustainability report reveals what the pharma industry is doing particularly well – and not so well – in its sustainability endeavors.
2026 Nasal & Inhalation Drug Development & Delivery eBook: Drug Repurposing Creates New Market Opportunities
In this exclusive seventh annual nasal and inhalation eBook, Drug Development & Delivery highlights how these routes of administration are bringing new life to orphaned drugs and open new opportunities for treatment beyond pulmonary and respiratory diseases. We also explore the challenges of nose-to-brain delivery, next-generation propellants, overcoming the limitations of dry powder inhalers, and successful formulation strategies.
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Connecting Your Project to the Right Service Provider
Outsourcing formulation development and manufacturing can help drug developers address complex dosage forms, scale-up risks, regulatory demands, and accelerated timelines by connecting projects with CDMO partners that offer specialized expertise, integrated workflows, and scalable manufacturing support.
SPECIAL REPORT - Advancements in Respiratory Drug Delivery
Advances in inhaled drug delivery are improving how therapies reach the lungs, with innovations in formulations, devices, biologics, and digital tools helping expand treatment options for respiratory diseases.
Expert Insights Videos
Go beyond the written word with our new podcast series, featuring in-depth conversations with industry leaders shaping the future of drug development and delivery. Each episode explores real-world challenges, emerging technologies, and the insights driving innovation across the pharmaceutical landscape.
Oral Peptide Drug Delivery: Overcoming Bioavailability & Formulation Challenges
The pharmaceutical industry is increasingly exploring oral delivery as an alternative to injections for peptides, proteins, oligonucleotides, and other complex molecules—but significant formulation and biological…
The Future of Injection Devices: Key Trends Shaping Drug Delivery
Injection devices continue to evolve as pharmaceutical companies look for more effective, convenient, and patient-focused ways to deliver increasingly complex therapies.
EXPERT CONTENT & RESOURCES
Whether you're a researcher, a pharmaceutical professional, or simply interested in the latest advancements in drug development and delivery technology, you'll find a wealth of insightful expertise and current resources here.
Case study: Modeling polymor interactions to improve amorphous dispersion design
In this case study, OSDPredict™ narrowed formulation options early, focusing development on the most viable strategies which reduced experimental burden and conserved valuable materials.
The Last Mile of Digital Implementation: A Technical Framework for Turning Clinical Technology Adoption Into Measurable Value
As clinical trials become increasingly digitally enabled, organizations must look beyond successful technology deployment to determine whether new tools are delivering measurable value. This article presents a five-layer framework for evaluating technical fitness, workflow integration, adoption, data reliability, and operational outcomes to help translate clinical technology investments into better trial execution and evidence.
FROM ASSESSMENT TO SUSTAINABLE ACTION - Circular Economy Strategies & Practical Routes to Lower-Impact Medical Devices
AstraZeneca and Novo Nordisk have both committed to science-based net-zero across their full value chains by 2045. However, decarbonizing manufacturing alone leaves most of the footprint untouched. Meeting these net-zero targets requires changes to the products themselves, the devices that deliver them, and the systems built around them, including the reprocessing and reuse networks. The route to a more sustainable device is not the same for every product, and the single biggest determinant of what is achievable is where a device sits in its product development lifecycle when sustainability is first considered.
Managing Fragmented Small-Molecule Supply Chains Through Strategic Secondary Bulk Packaging
As small-molecule manufacturing becomes increasingly fragmented across regions, specialist facilities, and CDMOs, every product handoff introduces new opportunities for delay and variability. A strategic bulk secondary packaging approach can help standardize product handling, improve operational control, and strengthen resilience across complex pharmaceutical supply chains.
Four Myths About Embedded CMOs, Busted
Are your perceptions of the CMO marketplace serving your drug program—or holding it back? If you’re looking for a contract manufacturer to bring your therapy to market, you’re far from alone. Demand for manufacturing services is shaping the pharma Contract Manufacturing Industry, with analysts predicting a growth rate of nearly 7% per year until 2028. In such a competitive market, how should a project sponsor navigate the choice between one CMO and another? To find the answer, many sponsors begin by distinguishing between typical stand-alone CMOs and an embedded CMO that operates under a parent company—AbbVie, in the case of AbbVie Contract Manufacturing (AbbVie).
Have expert content to share? Contact us
WHITEPAPERS & WEBINARS
WHITEPAPER - Large-Scale LNP Process Conversions
Large-Scale LNP Process Conversions: The many hurdles of LNP scale-up and what to consider Lipid nanoparticle (LNP) formulation development begins on a small scale, often…
WEBINAR - Challenges of Sustained Release Drug Delivery Devices
Sustained release drug delivery is rapidly expanding across respiratory, ophthalmic, transdermal, and implantable applications, but translating products from development to manufacturing remains both complex and…
WHITEPAPER - Streamlined Product Development Leveraging Pharmaceutical Classification Models
A technology agnostic approach based on a fundamental understanding of API properties, a well-defined yet flexible target product profile, and a mindset for scalability and…
WEBINAR ON DEMAND - Heat Without Harm: The Reality of Hot Melt Extrusion Webinar
In a 2025 industry survey (1), 76% of respondents selected ‘risk of thermal degradation’ as a source of hesitation to pursue hot melt extrusion (HME). Concerns about heat-sensitive APIs frequently lead development teams to rule out HME early — often before conducting a thorough scientific evaluation of their formulation options.
But thermal risk is frequently overstated. In this on-demand webinar, Stefanie Hauck, Senior Director PDS&T Pharm. Tech. at AbbVie Contract Manufacturing, explains why many compounds initially considered unsuitable for HME can be successfully processed with the right expertise.
WHITEPAPER - Container Closure Integrity Issues in Cell & Gene Therapy Products
The cell and gene therapy (CGT) product market is expected to grow at a very high rate of around 20-30% per year over the next 10 years. Increasing number of approvals, expansion of target diseases, accelerated investment and innovation, and advent of aging population are the key factors for the growth.
WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development
This on-demand webinar focuses on how data-driven characterization, predictive modeling, and Quality by Design (QbD) approaches help teams identify and address risks earlier—when decisions are more flexible and impacts easier to manage, before scale-up begins.
eBook - An Introduction to PLG Polymers for Long‑Acting Drug Delivery
Bioabsorbable poly(lactide-co‑glycolide) (PLG) polymers and poly(lactic acid-co-glycolic acid) (PLGA) have become an essential part of modern healthcare. Over the past five decades, these polymers have…
WHITEPAPER - From Service Provider to Strategic Partner
As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability.
MARKET NEWS & TRENDS
Lonza Capsugel Introduces Integrated Approach to Nitrosamine Risk Assessment
Pharmaceutical manufacturers evaluating potential nitrosamine formation in drug products can now access nitrite testing and related scientific and regulatory support through a new integrated service…
Schreiner MediPharm Introduces Multifunctional Security Label for GLP-1 Pens and Autoinjectors
As demand for injectable GLP-1 therapies continues to expand, pharmaceutical manufacturers are facing increased requirements for product authentication, tamper evidence, usability, and supply-chain visibility. Schreiner…
Recipharm, CanVirex Advance Manufacturing Development for Oncolytic Measles Virus Therapy
Recipharm and Swiss biotechnology company CanVirex are collaborating to develop a scalable manufacturing process for an oncolytic measles virus candidate being developed for the treatment…
Eli Lilly Breaks Ground on $6.5B Houston API Facility to Scale Oral GLP-1 and Genetic Medicines
Eli Lilly and Company has officially broken ground on a massive $6.5 billion active pharmaceutical ingredient (API) manufacturing campus in Houston, Texas. The facility marks…
Magnitude Biosciences Secures $1.72M to Scale C. elegans High-Throughput In Vivo Screening Platform
Contract research organization and Durham University spinout Magnitude Biosciences has closed a $1.72 million investment round to accelerate the commercial scale-up of its flagship in…
SCHOTT Pharma and Nemera Co-Develop Integrated 5.5 mL Syringe and Safety Platform to Advance At-Home Biologic Delivery
As biopharma accelerates the transition from hospital-based intravenous (IV) infusions to at-home subcutaneous administration, containment and delivery specialists SCHOTT Pharma and Nemera have partnered to…
Bespak, Upperton Team Up on Integrated Nasal Drug Product Development
Bespak and Upperton are combining their respective drug-development capabilities in a new collaboration aimed at helping pharmaceutical companies move nasal drug products from early formulation…
Kincell Bio, Cellipont Bioservices Complete Merger to Create Kincellis Advanced Therapies
Kincell Bio and Cellipont Bioservices have completed their previously announced merger, bringing the two advanced-therapy organizations together under a new company, Kincellis Advanced Therapies. The…
AI Algorithm Guides Modified-Release Tablet Design in Ongoing Clinical Study
An artificial intelligence algorithm has selected modified-release tablet formulations and dose levels during an ongoing clinical study, according to interim findings reported by Quotient Sciences.…
Upperton Secures MHRA Approval for New Sterile Manufacturing Facility
CDMO Upperton Pharma Solutions has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to begin GMP manufacture of sterile investigational medicinal…
New Hovione Facility Expands U.S. Capacity for Poorly Soluble Drug Development
CDMO Hovione has opened a new 31,000-square-foot facility at its East Windsor, New Jersey campus, doubling its US spray drying capacity as the company expands…
RSSL Launches Pharmaceutical Consultancy Service to Support Complex Drug Development and Manufacturing Challenges
Reading Scientific Services Ltd (RSSL) has launched a dedicated pharmaceutical consultancy offering aimed at helping pharmaceutical, biopharmaceutical and advanced therapy companies address increasingly complex challenges…
Zeteo Biomedical Takes Active Powder Delivery Platform Into Pulmonary Market
Zeteo Biomedical is moving beyond nasal drug delivery and into pulmonary applications with AriesMR, a reloadable dry powder inhaler intended to actively disperse pharmaceutical powders…
AI Failures Cost Life Sciences Organizations Millions as Process Gaps Persist
Artificial Intelligence adoption is accelerating across the healthcare and life sciences sectors, but poorly designed processes are emerging as a major obstacle to successful implementation,…
Ecolab Adds Resin Manufacturing Capacity With New Quzhou Facility
Ecolab is expanding its manufacturing and R&D footprint in China with the opening of a new resin production facility in Quzhou, a move aimed at…
Novo Nordisk Launches ‘Novo’ Rebrand to Sharpen Global Identity
Novo Nordisk is repositioning its corporate identity as it prepares for what the company describes as its next chapter, introducing a new brand platform, adopting…
BioLife Wins US Patent for Effervescent Oral Peptide Delivery Platform
BioLife has received a US patent for an effervescent tablet technology intended to enable oral delivery of peptide therapeutics, including GLP-1 receptor agonists used in…
AbbVie Strengthens Dermatology and Respiratory Pipeline With Apogee Acquisition
AbbVie has completed its acquisition of Apogee Therapeutics, adding a portfolio of long-acting antibody programs to its immunology and inflammation pipeline as the pharmaceutical company…
Lonza to Add Commercial Spray-Drying Capacity at Oregon Manufacturing Site
Constructed is expected to be completed on two new PSD-4 units that will expand Lonza’s US-based capacity for spray-dried dispersions, as drug developers face increasing…
Sandoz Plans Biosimilar Drug Substance Facility in Slovenia
Sandoz is planning a roughly $300 million investment in a new biosimilar drug substance manufacturing facility in Ljubljana, Slovenia, as the company moves to expand…
